0000000000528730

AUTHOR

Giovanni Spadafora

showing 4 related works from this author

Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the H…

1994

Thirty evaluable patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck region previously treated with cisplatin-based chemotherapy were treated with a combination of methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy. Besides surgery and/or radiotherapy all patients had previously received chemotherapy as induction therapy or as palliation for recurrent disease. Only 20% of patients achieved a partial objective response with a mean duration of 5.6 months (range 3.2-6.2), and 30% of patients had a stabilization of disease with a mean duration of 4.2+ months (range 3.8-6.0). Patients who responded had rhinopharyngeal carcinoma…

AdultMaleOncologymedicine.medical_specialtyVomitingmedicine.medical_treatmentVinblastineBleomycinSecond line chemotherapyMetastasisBleomycinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansBasal cellHead and neckAgedEpirubicinCisplatinStomatitisChemotherapybusiness.industryPalliative CareRemission InductionHead and neck cancerLeukopeniaMiddle Agedmedicine.diseaseCombined Modality TherapySurvival RateMethotrexateOtorhinolaryngologychemistryHead and Neck NeoplasmsCarcinoma Squamous CellFemaleFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugORL
researchProduct

Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy

1992

After informed consent 21 patients with advanced head and neck cancer resistant to folinic acid/5-fluorouracil (FA/5FU + cisplatin) were treated with weekly FA/5FU plus low dose hydroxyurea (HU) to evaluate if HU could further modulate 5FU antineoplastic activity. Five patients achieved a partial response (23.8%) which was short-lived (mean duration 6.5 months). Three patients (14%) had stable disease and 13 (62%) progressed. Among responders, four patients had epidermoidal carcinoma and one had clear cell carcinoma. Treatment was well tolerated and 5FU-related toxicity was not apparently worsened by the addition of HU. The most frequent toxicities were nausea/vomiting (81%), diarrhea (52%)…

MaleOncologyCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaPharmacology (medical)AgedAged 80 and overPharmacologyChemotherapyLeukopeniabusiness.industryMiddle Agedmedicine.diseaseSurvival RateOncologyHead and Neck NeoplasmsFluorouracilClear cell carcinomaVomitingFemaleFluorouracilmedicine.symptombusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.

1992

Twenty-two patients with advanced head and neck carcinoma were treated with 5FU 400 mg-2 m-1 week and folinic acid 500 mg m-2 week-1 plus CDDP in escalating doses from 20 to 40 mg m-2 week-1 without forced diuresis. Reduced gluthatione at the dose of 1.5 g m-2 was employed to protect patients from CDDP-related nephrotoxicity. The aims of the study were: a) to evaluate the therapeutic efficacy of this schedule, and b) to evaluate reduced gluthatione as uroprotector. Out of 20 evaluable patients 14 (70 %) had a major objective response. A CR with a mean duration of 9.0+ months was achieved in 15 % of the patients, a PR of 5.8+ months in 55 % of the patients, while 3 patients had stable diseas…

MaleCancer Researchmedicine.medical_specialtyUrologyLeucovorinHead/neck cancerDrug Administration ScheduleNephrotoxicityCatalysiFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientPharmacology (medical)NephrotoxicityAgedCisplatinHematologyDose-Response Relationship Drugbusiness.industryHead and neck cancerChemistry (all)Folinic acidMiddle Agedmedicine.diseaseGlutathioneOncologyFluorouracilHead and Neck NeoplasmsAnesthesiaPharmacology Toxicology and Pharmaceutics (all)ToxicityFemaleKidney DiseasesFluorouracilGluthationeCisplatinbusinessmedicine.drugMedical oncology and tumor pharmacotherapy
researchProduct

A Phase II Study of Levofolinic Acid and 5-Fluorouracil Plus Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma

1993

Forty patients with advanced squamous cell carcinoma of the head and neck (SCHNC) were treated with a combination of levofolinic acid 100 mg/m2+5-fluorouracil 375 mg/m2 in a 4-hour infusion plus cisplatin 20 mg/m2 in a 2-hour infusion for 5 consecutive days, repeated every 21-28 days. In the group of 20 previously untreated patients, a 90% overall response rate (ORR) with a 30% complete response rate (CRR) was obtained. In the group of 20 pretreated patients with recurrent and/or metastatic SCHNC, a 55% ORR with 15% CRR was achieved. This treatment was given on an outpatient basis and was generally very well tolerated with only 2 patients requiring hospitalization. Grade 1-2 gastrointestina…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentLeucovorinPhases of clinical researchInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientHead and neckAgedNeoplasm StagingCisplatinChemotherapybusiness.industryStereoisomerismGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyHead and neck squamous-cell carcinomaOncologyHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellFemaleFluorouracilCisplatinbusinessLevofolinic acidmedicine.drugOncology
researchProduct